Daxor acquires worldwide rights to Volumex, Megatope, and Glofil from Iso-Tex Diagnostics

DAXOR CORP

No upfront payment; seller-financed with monthly installments starting after manufacturing transition in 6–9 months.
Deal expected to be immediately accretive and cash flow positive due to higher margins from in-house production.
Glofil (GFR diagnostic) adds recurring revenue stream and cross-selling opportunity to existing hospital customers.
Volumex and Megatope radiopharmaceuticals for blood volume analysis will be produced at Daxor's Oak Ridge facility.
Transaction subject to customary closing conditions including applicable regulatory approvals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.